Palvella Therapeutics (PVLA) Non-Current Deffered Revenue (2016 - 2023)
Historic Non-Current Deffered Revenue for Palvella Therapeutics (PVLA) over the last 8 years, with Q2 2023 value amounting to $759000.0.
- Palvella Therapeutics' Non-Current Deffered Revenue fell 9655.99% to $759000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $759000.0, marking a year-over-year decrease of 9655.99%. This contributed to the annual value of $18.7 million for FY2022, which is 5121.74% down from last year.
- Latest data reveals that Palvella Therapeutics reported Non-Current Deffered Revenue of $759000.0 as of Q2 2023, which was down 9655.99% from $11.7 million recorded in Q1 2023.
- In the past 5 years, Palvella Therapeutics' Non-Current Deffered Revenue registered a high of $59.7 million during Q1 2019, and its lowest value of $759000.0 during Q2 2023.
- Its 5-year average for Non-Current Deffered Revenue is $34.9 million, with a median of $37.4 million in 2020.
- As far as peak fluctuations go, Palvella Therapeutics' Non-Current Deffered Revenue surged by 3058.79% in 2021, and later crashed by 9655.99% in 2023.
- Palvella Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $47.3 million in 2019, then decreased by 24.03% to $35.9 million in 2020, then increased by 6.97% to $38.4 million in 2021, then tumbled by 51.22% to $18.7 million in 2022, then tumbled by 95.95% to $759000.0 in 2023.
- Its last three reported values are $759000.0 in Q2 2023, $11.7 million for Q1 2023, and $18.7 million during Q4 2022.